Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 127 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glomerular Disease Clear all
Recruiting Phase 3 Interventional

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

NCT06858319
View directory record Official record
Conditions
Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease
Interventions
zigakibart
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
8
States / cities
Denver, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

NCT02017171
View directory record Official record
Conditions
Diabetic Nephropathies, Coronary Artery Disease
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

NCT06675175
View directory record Official record
Conditions
Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease
Interventions
AZD4144, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
9
States / cities
Glendale, California • Daytona Beach, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Not applicable Interventional

Medication Intervention in Transitional Care to Optimize Outcomes & Costs for CKD & ESRD

NCT01459770
View directory record Official record
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
Medication Information Transfer Intervention, Usual care for hospital discharge
Other
Lead sponsor
Providence Medical Research Center
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Daratumumab in Treatment of PGNMID and C3 GN

NCT03095118
View directory record Official record
Conditions
Membranoproliferative Glomerulonephritis
Interventions
Daratumumab
Drug
Lead sponsor
Fernando Fervenza
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria

NCT00625820
View directory record Official record
Conditions
Kidney Disease, Albuminuria
Interventions
6R BH4, Vitamin C
Drug · Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Sep 15, 2026, 10:27 AM EDT
Completed No phase listed Observational

Alport Syndrome Treatments and Outcomes Registry

NCT00481130
View directory record Official record
Conditions
Alport Syndrome
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
0 Years to 99 Years
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 15, 2026, 10:27 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of LY3971297 in Healthy Participants

NCT06148272
View directory record Official record
Conditions
Healthy, Obesity, Hypertension
Interventions
LY3971297, Placebo, LY3971297 IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

NCT05425719
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
5
States / cities
Edgewater, Florida • Chicago, Illinois • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Not applicable Interventional

Effect of Low Frequency Ultrasound on Kidney Function

NCT02026544
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Low Frequency Therapeutic Ultrasound
Device
Lead sponsor
Sonogenix
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 15, 2026, 10:27 AM EDT
Terminated Not applicable Interventional Results available

Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)

NCT02503735
View directory record Official record
Conditions
Hepatitis C, Chronic Kidney Disease
Interventions
Sofosbuvir/Ledipasvir FDC
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

NCT02795676
View directory record Official record
Conditions
Fabry Disease
Interventions
PRX-102 (pegunigalsidase alfa), agalsidase beta
Biological
Lead sponsor
Protalix
Industry
Eligibility
18 Years to 60 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting No phase listed Observational

ASF Alport Patient Registry

NCT06526741
View directory record Official record
Conditions
Alport Syndrome, Thin Basement Membrane Disease, Hereditary Nephritis
Interventions
Longitudinal data collection
Other
Lead sponsor
Alport Syndrome Foundation
Other
Eligibility
0 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2048
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Withdrawn Not applicable Interventional

Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease

NCT01426724
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Contrast Enhanced Ultrasonography
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

NCT00976495
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo, Hydrochlorothiazide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Anaheim, California • Lomita, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 15, 2026, 10:27 AM EDT
Not yet recruiting Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate

NCT01163162
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Paricalcitol
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting Phase 3 Interventional

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

NCT04817618
View directory record Official record
Conditions
C3G
Interventions
Placebo, iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Aurora, Colorado • Miami, Florida • Lawrenceville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Obesity and Protein Intake on the Kidney

NCT00244790
View directory record Official record
Conditions
Kidney Diseases
Interventions
Diet
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Sep 15, 2026, 10:27 AM EDT
Completed No phase listed Observational

Evaluation of New Test Method to Measure Kidney Function

NCT00026715
View directory record Official record
Conditions
Kidney Disease
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 15, 2026, 10:27 AM EDT
Completed No phase listed Observational

Kidney Disease Biomarkers

NCT00255398
View directory record Official record
Conditions
Kidney Disease, Glomerular Disease, Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Collapsing Glomerulopathy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 15, 2026, 10:27 AM EDT
Completed No phase listed Observational

Pathogenesis of Glomerulosclerosis

NCT00001392
View directory record Official record
Conditions
Glomerular Disease
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Not applicable Interventional Results available

Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation

NCT00428246
View directory record Official record
Conditions
Chronic Kidney Disease, Endothelial Dysfunction, Inflammation, Hypertension
Interventions
paricalcitol, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting Phase 2 Interventional

Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT06466135
View directory record Official record
Conditions
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Interventions
WAL0921, Placebo
Drug
Lead sponsor
Walden Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 15, 2026, 10:27 AM EDT